Market Overview:
The global levetiracetam API market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of seizures and other neurological disorders, rising demand for levetiracetam as an adjunctive therapy, and growing investments by pharmaceutical companies in R&D activities for new drug formulations. Based on type, the global levetiracetam API market can be segmented into purity ≥98%.
Product Definition:
Levetiracetam API is the active pharmaceutical ingredient in Keppra, a prescription medication used to treat epilepsy. The importance of Levetiracetam API lies in its ability to help control seizures in people with epilepsy.
Purity≥98%:
Purity 98% is a crystalline powder, which is derived from ketones. It has the same molecular formula as that of levetiracetam (LVC). Purity 98% contains almost the same amount of active ingredient as compared to levetiracetam. The only difference between them being their different crystal forms and particle sizes.
Purity
Purity 98% is a high purity form of levetiracetam manufactured by GSK. It contains almost the same amount of drug as in original Levetiracetam API, but with few exceptions. Purity level above 99% is rare and it’s only found in a few drugs like Epoetin Alfa (Epogen), Procrit (Proliferant), and some other medicines for blood cancer.
Application Insights:
On the basis of application, the global market has been segmented into levetiracetam tablets, injections and others. The tablets were estimated to be the largest revenue generating segment in 2017 with a share of over 60%. Levetiracetam injection is used for treating patients who cannot take oral medication or cannot tolerate its side effects. Other applications include use as an add-on therapy to improve seizure control in patients suffering from epilepsy and other neurological disorders.
The growing usage of levothyroxine sodium as a replacement therapy for hypothyroidism due to increasing awareness among individuals regarding this condition is expected to drive demand over the forecast period. Increasing prevalence of neurological disorders coupled with rising adoption of advanced therapies such as levothyroxine sodium are anticipated to boost product demand globally during future years.
Regional Analysis:
Europe was the largest regional market in 2017 owing to the presence of key manufacturers and a well-established healthcare sector. The region is expected to maintain its dominance over the forecast period due to increasing R&D activities and product launches. For instance, in February 2018, Sun Pharma launched generic version of Keppra (levetiracetam) tablets under brand name SUnofiq CT200 & CT500. Asia Pacific is anticipated to be one of the fastest growing regions with a CAGR exceeding 6% from 2018 to 2030 owing rising incidence of Alzheimer’s disease (AD) coupled with expanding patient base for generic drugs in this region. In November 2016, Sun Pharmaceutical Industries Ltd., India based pharmaceutical company launched levetiracetam oral capsule formulation under brand name Uptravi which is approved by Australian Therapeutics Good Administration (TGA).
Growth Factors:
- Increasing incidence of epilepsy and seizures: The global prevalence of epilepsy is estimated to be around 50 million, and the number of people with seizures is even higher. This number is expected to grow in the coming years due to various factors such as population growth, aging population, and increasing awareness about epilepsy. This will create a large pool of patients who could benefit from levetiracetam therapy, driving its demand.
- Growing use of levetiracetam in pediatric patients: Levetiracetam has been found to be safe and effective for use in pediatric patients with various types of seizures. Its growing use in this population will fuel its demand over the forecast period.
- Rising adoption of monotherapy over polytherapy: Monotherapy refers to the use of a single drug for treatment instead of multiple drugs simultaneously (polytherapy). Levetiracetam has been found to be efficacious as monotherapy for various typesof seizures, which is likelyto drive its adoption overthe forecast periodover other therapies options available currently.. 4) Availability as generic drug: Levetiracetam is available as a generic drug in many countries across the globe,.This will help make it more affordablefor patients, boostingitsdemandin these markets 5) Increasing research on levetiracetams potential therapeutic applications: Ongoing research onle vet ir acet ams potential therapeutic applications beyond seizure disorderswill provide new indications for thisdrug therapyand boostitsdemand
Scope Of The Report
Report Attributes
Report Details
Report Title
Levetiracetam API Market Research Report
By Type
Purity≥98%, Purity<98%
By Application
Levetiracetam Tablets, Levetiracetam Injections, Others
By Companies
Dr. Reddy’s Laboratories Ltd., Solara Active Pharma Sciences, Divis Laboratories Ltd., Apeloa Pharmaceutical Co., Ltd., Jiangbei Pharmaceutical, Amoli Organics, Zhejiang Huahai Pharmaceuticals Co., Ltd, Neuland Laboratories, Srini Pharmaceuticals, Orchid Chemicals & Pharmaceuticals, SMS Pharmaceuticals, Second Pharma Co., Ltd., Chongqing Shenghuaxi Pharmaceutical Co., Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
151
Number of Tables & Figures
106
Customization Available
Yes, the report can be customized as per your need.
Global Levetiracetam API Market Report Segments:
The global Levetiracetam API market is segmented on the basis of:
Types
Purity≥98%, Purity<98%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Levetiracetam Tablets, Levetiracetam Injections, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Dr. Reddy’s Laboratories Ltd.
- Solara Active Pharma Sciences
- Divis Laboratories Ltd.
- Apeloa Pharmaceutical Co., Ltd.
- Jiangbei Pharmaceutical
- Amoli Organics
- Zhejiang Huahai Pharmaceuticals Co., Ltd
- Neuland Laboratories
- Srini Pharmaceuticals
- Orchid Chemicals & Pharmaceuticals
- SMS Pharmaceuticals
- Second Pharma Co., Ltd.
- Chongqing Shenghuaxi Pharmaceutical Co., Ltd
Highlights of The Levetiracetam API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity≥98%
- Purity<98%
- By Application:
- Levetiracetam Tablets
- Levetiracetam Injections
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Levetiracetam API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Levetiracetam API is an oral drug that is used to treat seizures in adults. It works by slowing down the activity of the brain and spinal cord.
Some of the major companies in the levetiracetam api market are Dr. Reddy’s Laboratories Ltd., Solara Active Pharma Sciences, Divis Laboratories Ltd., Apeloa Pharmaceutical Co., Ltd., Jiangbei Pharmaceutical, Amoli Organics, Zhejiang Huahai Pharmaceuticals Co., Ltd, Neuland Laboratories, Srini Pharmaceuticals, Orchid Chemicals & Pharmaceuticals, SMS Pharmaceuticals, Second Pharma Co., Ltd., Chongqing Shenghuaxi Pharmaceutical Co., Ltd.
The levetiracetam api market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Levetiracetam API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Levetiracetam API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Levetiracetam API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Levetiracetam API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Levetiracetam API Market Size & Forecast, 2020-2028
4.5.1 Levetiracetam API Market Size and Y-o-Y Growth
4.5.2 Levetiracetam API Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Purity≥98%
5.2.2 Purity<98%
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Levetiracetam Tablets
6.2.2 Levetiracetam Injections
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Levetiracetam API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Levetiracetam API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Purity≥98%
9.6.2 Purity<98%
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Levetiracetam Tablets
9.10.2 Levetiracetam Injections
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Purity≥98%
10.6.2 Purity<98%
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Levetiracetam Tablets
10.10.2 Levetiracetam Injections
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Purity≥98%
11.6.2 Purity<98%
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Levetiracetam Tablets
11.10.2 Levetiracetam Injections
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Purity≥98%
12.6.2 Purity<98%
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Levetiracetam Tablets
12.10.2 Levetiracetam Injections
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Purity≥98%
13.6.2 Purity<98%
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Levetiracetam Tablets
13.10.2 Levetiracetam Injections
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Levetiracetam API Market: Competitive Dashboard
14.2 Global Levetiracetam API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Dr. Reddy’s Laboratories Ltd.
14.3.2 Solara Active Pharma Sciences
14.3.3 Divis Laboratories Ltd.
14.3.4 Apeloa Pharmaceutical Co., Ltd.
14.3.5 Jiangbei Pharmaceutical
14.3.6 Amoli Organics
14.3.7 Zhejiang Huahai Pharmaceuticals Co., Ltd
14.3.8 Neuland Laboratories
14.3.9 Srini Pharmaceuticals
14.3.10 Orchid Chemicals & Pharmaceuticals
14.3.11 SMS Pharmaceuticals
14.3.12 Second Pharma Co., Ltd.
14.3.13 Chongqing Shenghuaxi Pharmaceutical Co., Ltd
